News | September 20, 2010

Standardization Technology Will Increase Accuracy in Evaluating Tumor Progression

September 20, 2010 – A newly signed agreement may lead to an automated way to more accurately evaluate a tumor's response to various treatment therapies.

Imaging Biometrics LLC (IB), a provider of advanced visualization and analytical software solutions for the medical industry, signed an exclusive global license agreement with the University of Pennsylvania that grants IB the right to develop and commercialize the technology. Developed by professor Jay Udupa, Ph.D., University of Pennsylvania School of Medicine, the technology “standardizes” images on a voxel-by-voxel basis, which is a necessary step when wanting to accurately compare images over time.

Essentially, the technology may make it unnecessary for the radiologist to perform time-consuming manipulations that make the image brightness levels more similar across time. When automated, this technique may reliably remove subjective and intra- and inter-scanner variability when monitoring patients with tumors.

The introduction of this technology is quite timely since the conventional approach for tracking changes in tumors over time is becoming more challenging, due to the introduction of new treatments that target the tumor vessels. As the use of these anti-angiogenic agents increases, so does the difficulty in identifying subtle changes in tumor progression. This is because these drugs may also make the uptake of the MRI dye more difficult to see in tumors. By leveraging this technology, IB’s approach, called the delta T1 method (dTM), will make it faster and easier for clinicians to distinguish changes and, therefore, enable better decision making and more precise treatment planning for their patients.

The technology will be incorporated into several IB-branded products, including IB Suite; an image analysis toolkit currently under development.

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...